Alsamil, A.M.; Giezen, T.J.; Egberts, T.C.; Leufkens, H.G.; Gardarsdottir, H.
Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab Biosimilars. Pharmaceuticals 2021, 14, 189.
https://doi.org/10.3390/ph14030189
AMA Style
Alsamil AM, Giezen TJ, Egberts TC, Leufkens HG, Gardarsdottir H.
Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab Biosimilars. Pharmaceuticals. 2021; 14(3):189.
https://doi.org/10.3390/ph14030189
Chicago/Turabian Style
Alsamil, Ali M., Thijs J. Giezen, Toine C. Egberts, Hubert G. Leufkens, and Helga Gardarsdottir.
2021. "Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab Biosimilars" Pharmaceuticals 14, no. 3: 189.
https://doi.org/10.3390/ph14030189
APA Style
Alsamil, A. M., Giezen, T. J., Egberts, T. C., Leufkens, H. G., & Gardarsdottir, H.
(2021). Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab Biosimilars. Pharmaceuticals, 14(3), 189.
https://doi.org/10.3390/ph14030189